Could dyslipidemic children benefit from glucomannan intake?

Guardamagna, Ornella; Abello, Francesca; Cagliero, Paola; Visioli, Francesco

doi:10.1016/j.nut.2013.02.010

Cited by 24 publications

(12 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These trials show how the use of glucomannan and psyllium influences the lipid profile. Results are very different in both situation, ranging from −5% [8,16] to −18% [9,13] for the TC and from −6.8% [16] to −24% [11] for the LDL-C. These variations could be related to study design differences including the subjects diagnosis and age variability, limited number of patients, different fiber dosages and treatment period.…”

Section: Resultsmentioning

confidence: 91%

“…These variations could be related to study design differences including the subjects diagnosis and age variability, limited number of patients, different fiber dosages and treatment period. Generally with the administration of 0.5 g of glucomannan once a day for 9 weeks [9], until a maximum of 24 weeks of treatment twice a day [8], we can observe a significant reduction of TC and LDL-C levels. Comparing TC and LDL-C levels in these studies, similar results are obtained with a long period treatment, maybe due to the reaching of a balance of the metabolism.…”

Section: Resultsmentioning

confidence: 96%

“…In these studies there are controversial results about the atherogenic factor Apolipoprotein B (ApoB): in fact in some trials it does not change [8] or it is not measured, and in others it is decreased [3,15].…”

Section: Resultsmentioning

confidence: 99%

“…Dietary fiber is a relevant dietary component, with several health benefits in both adults and children. It promotes gastrointestinal function and helps to reduce the risk of cardiovascular diseases by decreasing serum TC and LDL-C concentrations: in particular, various studies proved that a Child-1 diet associated with 0.5 g/day of glucomannan reduces TC and LDL-C to 10% [8][9][10], and 6 gr of psyllium reduce TC of 16% -18% and LDL-C of 22% -24% [11][12][13]. Generally dietary fiber intake has no effect on High-Density Lipoprotein Cholesterol (HDL-C) or triglyceride (Tg) concentrations, but lowers serum insulin concentrations and reduces the risk of obesity and type 2 diabetes.…”

Section: Functions and Mechanisms Of Actionmentioning

confidence: 99%

See 3 more Smart Citations

Nutraceuticals in Hypercholesterolemic children

Cagliero¹,

Calosso²,

Brunatti³

et al. 2013

Health

Self Cite

View full text Add to dashboard Cite

Hypercholesterolemia is associated with the atherosclerotic process and cardiovascular disease from childhood, thus introducing the need of an early prevention. The dietary approach is the treatment cornerstone but sometimes is unsuccessful to reach the lipoprotein optimal target. Furthermore, drugs like statins have limited use in childhood as their administration is limited to high risk children. The effects of nutraceuticals are known in adults and considered useful in children to overcome this therapy gap. In the present paper a review of pediatric experiences from fiber, phytosterols and RYR handing out is considered.

show abstract

Section: Resultsmentioning

confidence: 91%

Section: Resultsmentioning

confidence: 96%

Section: Resultsmentioning

confidence: 99%

Section: Functions and Mechanisms Of Actionmentioning

confidence: 99%

See 2 more Smart Citations

Nutraceuticals in Hypercholesterolemic children

Cagliero¹,

Calosso²,

Brunatti³

et al. 2013

Health

Self Cite

View full text Add to dashboard Cite

show abstract

“…A number of effects of this substance on human health have been reported. KGM affects total cholesterol and fasting blood glucose beneficially (Sood, Baker, & Coleman, 2008;Guardamagna, Abello, Cagliero, & Visioli, 2013). Although its therapeutic uses need further investigation, glucomannan could be a candidate for treating a range of physiological disorders such as diverticulitis, Crohn's disease or ulcerative colitis (Tester & Al-Ghazzewi, 2013).…”

Section: Capítulo IVmentioning

confidence: 99%

Diseño de alimentos saciantes: estudio de las propiedades físicas, sensoriales y de la capacidad saciante esperada en un postre lácteo sólido tipo tarta de queso

Rodríguez¹,

Maria²

View full text Add to dashboard Cite

Superior de Investigaciones Científicas HACE CONSTAR QUE: El trabajo de investigación titulado "Diseño de alimentos saciantes: Estudio de las propiedades físicas, sensoriales y de la capacidad saciante esperada en un postre lácteo sólido tipo tarta de queso" que presenta Dña. Johanna María Marcano Rodríguez por la Universidad Politécnica de Valencia, ha sido realizado en el Instituto de Agroquímica y Tecnología de alimentos (IATA-CSIC) bajo mi dirección y que reúne las condiciones para optar al grado de Doctor. Valencia, septiembre de 2015 Fdo: Dra. Susana Fiszman Dal Santo Para y por Angelita, quien pasó como mágica estrella fugaz, dejando sembradas las semillas del amor por la vida, el saber y el aprender, huella imborrable y un manto de sagrada protección sobre sus dos niñas… Agradecimientos A Dios, por nutrirme como fuente de amor, seguridad y protección, por llevarme en sus brazos aligerando mi carga en los momentos en que lo he necesitado.A mi Directora Susana Fiszman, por ser la mejor fuente de inspiración y admiración, gran apoyo y segura mano amiga; por formar parte de mis más grandes afectos.A mi padre Douglas Eduardo, por haberme proporcionado las herramientas necesarias para afrontar la vida, por enseñarme a volar, por participar y disfrutar del camino que me ha llevado a la consecución de todos mis sueños; por eso y mucho mas este logro también es suyo.A mi hermana María Alejandra, por ser siempre razón y motor para lograr objetivos, por existir en mi vida, brindarme su amistad, amor y apoyo incondicional.A mi esposo Leduar, por el amor y el apoyo ofrecido, por compartir la calidez de nuestro hogar y ser razón de mi felicidad junto a nuestros niños.A Jesús Alberto, por la solidez, dulzura e incondicionalidad de su amistad. A mi amiga María Alejandra y a mi cuñado Sam, por todo el apoyo y el cariño ofrecido. A Claudia, Georgina, Sisy, Blanca y Mary Jane, por disfrutar y compartir nuestros logros y afecto, sin importar la distancia que nos separe. A mi tutora Isabel Hernando por toda la colaboración brindada en pro de la culminación de este proyecto. A los estudiantes que de algún modo compartieron y participaron en la fase de trabajo experimental (Sara, A trabajadores y colaboradores del Instituto de Agroquímica y Tecnología de Alimentos y a estudiantes y personal de la Universidad Politécnica de Valencia, quienes participaron activamente en las diferentes pruebas de evaluación sensorial efectuadas. Al Ministerio de Economía y Competitividad de España por la financiación prestada. A todos los trabajadores de la Universidad Politécnica de Valencia, por su valiosa y eficaz gestión, por recibirme y compartir esta fase de consolidación académica. Y finalmente pero no menos importante, a todo el personal del Consejo Superior de Investigaciones Científicas y del Instituto de Agroquímica y Tecnología de Alimentos, por acogerme como parte de sí y brindarme toda su colaboración. ResumenEl desarrollo de alimentos con mayores propiedades saciantes saludables, aceptables y de uso cotidiano, representa una importa...

show abstract

Screening for Lipid Disorders in Children and Adolescents

Evans

Coppola

Redmond

et al. 2023

JAMA

View full text Add to dashboard Cite

ImportanceLipid screening in childhood and adolescence can lead to early dyslipidemia diagnosis. The long-term benefits of lipid screening and subsequent treatment in this population are uncertain.ObjectiveTo review benefits and harms of screening and treatment of pediatric dyslipidemia due to familial hypercholesterolemia (FH) and multifactorial dyslipidemia.Data SourcesMEDLINE and the Cochrane Central Register of Controlled Trials through May 16, 2022; literature surveillance through March 24, 2023.Study SelectionEnglish-language randomized clinical trials (RCTs) of lipid screening; recent, large US cohort studies reporting diagnostic yield or screen positivity; and RCTs of lipid-lowering interventions.Data Extraction and SynthesisSingle extraction, verified by a second reviewer. Quantitative synthesis using random-effects meta-analysis.Main Outcomes and MeasuresHealth outcomes, diagnostic yield, intermediate outcomes, behavioral outcomes, and harms.ResultsForty-three studies were included (n = 491 516). No RCTs directly addressed screening effectiveness and harms. Three US studies (n = 395 465) reported prevalence of phenotypically defined FH of 0.2% to 0.4% (1:250 to 1:500). Five studies (n = 142 257) reported multifactorial dyslipidemia prevalence; the prevalence of elevated total cholesterol level (≥200 mg/dL) was 7.1% to 9.4% and of any lipid abnormality was 19.2%. Ten RCTs in children and adolescents with FH (n = 1230) demonstrated that statins were associated with an 81- to 82-mg/dL greater mean reduction in levels of total cholesterol and LDL-C compared with placebo at up to 2 years. Nonstatin-drug trials showed statistically significant lowering of lipid levels in FH populations, but few studies were available for any single drug. Observational studies suggest that statin treatment for FH starting in childhood or adolescence reduces long-term cardiovascular disease risk. Two multifactorial dyslipidemia behavioral counseling trials (n = 934) demonstrated 3- to 6-mg/dL greater reductions in total cholesterol levels compared with the control group, but findings did not persist at longest follow-up. Harms reported in the short-term drug trials were similar in the intervention and control groups.Conclusions and RelevanceNo direct evidence on the benefits or harms of pediatric lipid screening was identified. While multifactorial dyslipidemia is common, no evidence was found that treatment is effective for this condition. In contrast, FH is relatively rare; evidence shows that statins reduce lipid levels in children with FH, and observational studies suggest that such treatment has long-term benefit for this condition.

show abstract

Could dyslipidemic children benefit from glucomannan intake?

Cited by 24 publications

References 39 publications

Nutraceuticals in Hypercholesterolemic children

Nutraceuticals in Hypercholesterolemic children

Diseño de alimentos saciantes: estudio de las propiedades físicas, sensoriales y de la capacidad saciante esperada en un postre lácteo sólido tipo tarta de queso

Screening for Lipid Disorders in Children and Adolescents

Contact Info

Product

Resources

About